Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs

Authors: Kati Erdmann, Knut Kaulke, Cathleen Thomae, Doreen Huebner, Mildred Sergon, Michael Froehner, Manfred P Wirth, Susanne Fuessel

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certain genes such as AMACR, EZH2, PSGR, PSMA and TRPM8 could be associated with an aberrant expression of non-coding microRNAs (miRNA).

Methods

In silico analyses were used to search for miRNAs being putative regulators of PCa-associated genes. The expression of nine selected miRNAs (hsa-miR-101, -138, -186, -224, -26a, -26b, -374a, -410, -660) as well as of the aforementioned PCa-associated genes was analyzed by quantitative PCR using 50 malignant (Tu) and matched non-malignant (Tf) tissue samples from prostatectomy specimens as well as 30 samples from patients with benign prostatic hyperplasia (BPH). Then, correlations between paired miRNA and target gene expression levels were analyzed. Furthermore, the effect of exogenously administered miR-26a on selected target genes was determined by quantitative PCR and Western Blot in various PCa cell lines. A luciferase reporter assay was used for target validation.

Results

The expression of all selected miRNAs was decreased in PCa tissue samples compared to either control group (Tu vs Tf: -1.35 to -5.61-fold; Tu vs BPH: -1.17 to -5.49-fold). The down-regulation of most miRNAs inversely correlated with an up-regulation of their putative target genes with Spearman correlation coefficients ranging from -0.107 to -0.551. MiR-186 showed a significantly diminished expression in patients with non-organ confined PCa and initial metastases. Furthermore, over-expression of miR-26a reduced the mRNA and protein expression of its potential target gene AMACR in vitro. Using the luciferase reporter assay AMACR was validated as new target for miR-26a.

Conclusions

The findings of this study indicate that the expression of specific miRNAs is decreased in PCa and inversely correlates with the up-regulation of their putative target genes. Consequently, miRNAs could contribute to oncogenesis and progression of PCa via an altered miRNA-target gene-interaction.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Hori S, Blanchet JS, McLoughlin J: From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 2013, 112 (6): 717-728. 10.1111/j.1464-410X.2012.11329.x.CrossRefPubMed
3.
Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A: Quantitative multi-gene expression profiling of primary prostate cancer. Prostate. 2006, 66 (14): 1521-1534. 10.1002/pros.20490.CrossRefPubMed
4.
Schneider S, Voigt S, Fussel S, Lohse-Fischer A, Tomasetti S, Haase M, Koch R, Baretton GB, Grimm MO, Wirth MP: Molecular genetic markers for prostate cancer. Evidence in fine needle biopsies for improved confirmation of the diagnosis. Urologe A. 2008, 47 (9): 1208-1211. 10.1007/s00120-008-1837-8.CrossRefPubMed
5.
Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost AK, Weigle B, Kiessling A, Wirth MP: Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol. 2003, 23 (1): 221-228.PubMed
6.
Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U, Wirth MP, Rieber EP: Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate. 2003, 56 (4): 270-279. 10.1002/pros.10265.CrossRefPubMed
7.
Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR: P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001, 25 (11): 1397-1404. 10.1097/00000478-200111000-00007.CrossRefPubMed
8.
Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD: Alpha-methylacyl-CoA racemase–an ‘obscure’ metabolic enzyme takes centre stage. Febs J. 2008, 275 (6): 1089-1102. 10.1111/j.1742-4658.2008.06290.x.CrossRefPubMed
9.
Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, de Marzo AM, Isaacs WB: Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 2003, 63 (21): 7365-7376.PubMed
10.
Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008, 647 (1–2): 21-29.CrossRefPubMed
11.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002, 419 (6907): 624-629. 10.1038/nature01075.CrossRefPubMed
12.
Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP: Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006, 236 (2): 229-238. 10.1016/j.canlet.2005.05.021.CrossRefPubMed
13.
Weng J, Wang J, Cai Y, Stafford LJ, Mitchell D, Ittmann M, Liu M: Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer. 2005, 113 (5): 811-818. 10.1002/ijc.20635.CrossRefPubMed
14.
Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S: Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006, 9 (1): 56-61. 10.1038/sj.pcan.4500836.CrossRefPubMed
15.
Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, Colas E, Garcia M, Ruiz A, Abal M, Planas J, Reventos J, Doll A: PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate. 2010, 70 (16): 1760-1767.PubMed
16.
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998, 82 (11): 2256-2261. 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S.CrossRefPubMed
17.
Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA: Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007, 38 (5): 696-701. 10.1016/j.humpath.2006.11.012.CrossRefPubMed
18.
Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST: Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2012, 2012: 973820-CrossRefPubMed
19.
Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST: Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013, 31 (2): 144-154. 10.1016/j.urolonc.2012.04.016.CrossRefPubMed
20.
Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003, 63 (14): 4196-4203.PubMed
21.
Tsavaler L, Shapero MH, Morkowski S, Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 2001, 61 (9): 3760-3769.PubMed
22.
Zhang L, Barritt GJ: Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res. 2004, 64 (22): 8365-8373. 10.1158/0008-5472.CAN-04-2146.CrossRefPubMed
23.
Gregory RI, Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res. 2005, 65 (9): 3509-3512. 10.1158/0008-5472.CAN-05-0298.CrossRefPubMed
24.
Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6 (4): 259-269. 10.1038/nrc1840.CrossRefPubMed
25.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral
26.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702.CrossRefPubMed
27.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6 (11): 857-866. 10.1038/nrc1997.CrossRefPubMed
28.
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68 (15): 6162-6170. 10.1158/0008-5472.CAN-08-0144.CrossRefPubMedPubMedCentral
29.
Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G: Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012, 31 (8): 978-991. 10.1038/onc.2011.304.CrossRefPubMed
30.
Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67 (13): 6130-6135. 10.1158/0008-5472.CAN-07-0533.CrossRefPubMed
31.
Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stohr R, Hartmann A, Wullich B, Grasser F: The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 2010, 8 (4): 529-538. 10.1158/1541-7786.MCR-09-0443.CrossRefPubMed
32.
Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, Dyrskjot L, Eltze E, Wieland W, Keck B, Ekici AB, Grasser F, Wullich B: MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer. 2012, 130 (3): 611-621. 10.1002/ijc.26064.CrossRefPubMed
33.
Walter BA, Valera VA, Pinto PA, Merino MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer Educ. 2013, 4 (5): 350-357. 10.7150/jca.6394.CrossRef
34.
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007, 39 (5): 673-677. 10.1038/ng2003.CrossRefPubMed
35.
Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006, 25 (46): 6188-6196. 10.1038/sj.onc.1209913.CrossRefPubMed
36.
Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G: MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 2010, 9: 108-10.1186/1476-4598-9-108.CrossRefPubMedPubMedCentral
37.
Kisliouk T, Yosefi S, Meiri N: MiR-138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine 27, and affects thermotolerance acquisition. Eur J Neurosci. 2011, 33 (2): 224-235. 10.1111/j.1460-9568.2010.07493.x.CrossRefPubMed
38.
Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, de Marzo AM: Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011, 2 (9): 669-683.CrossRefPubMedPubMedCentral
39.
Liu X, Wang C, Chen Z, Jin Y, Wang Y, Kolokythas A, Dai Y, Zhou X: MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J. 2011, 440 (1): 23-31. 10.1042/BJ20111006.CrossRefPubMedPubMedCentral
40.
Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008, 322 (5908): 1695-1699. 10.1126/science.1165395.CrossRefPubMedPubMedCentral
41.
Carlsson J, Helenius G, Karlsson M, Lubovac Z, Andren O, Olsson B, Klinga-Levan K: Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues. Cancer Genet Cytogenet. 2010, 202 (2): 71-75. 10.1016/j.cancergencyto.2010.06.009.CrossRefPubMed
42.
Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008, 9: 76-10.1186/1471-2199-9-76.CrossRefPubMedPubMedCentral
43.
Mavridis K, Stravodimos K, Scorilas A: Downregulation and prognostic performance of MicroRNA 224 expression in prostate cancer. Clin Chem. 2013, 59 (1): 261-269. 10.1373/clinchem.2012.191502.CrossRefPubMed
44.
Kunze D, Kraemer K, Erdmann K, Froehner M, Wirth MP, Fuessel S: Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol. 2012, 41: 1271-1277.PubMedPubMedCentral
45.
Yao V, Parwani A, Maier C, Heston WD, Bacich DJ: Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res. 2008, 68 (21): 9070-9077. 10.1158/0008-5472.CAN-08-2328.CrossRefPubMedPubMedCentral
46.
Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K: MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol. 2010, 28 (1): 4-13. 10.1016/j.urolonc.2008.10.021.CrossRefPubMed
47.
Schaefer A, Stephan C, Busch J, Yousef GM, Jung K: Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol. 2010, 7 (5): 286-297. 10.1038/nrurol.2010.45.CrossRefPubMed
Metadata
Title
Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs
Authors
Kati Erdmann
Knut Kaulke
Cathleen Thomae
Doreen Huebner
Mildred Sergon
Michael Froehner
Manfred P Wirth
Susanne Fuessel
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-82

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Serum glucose and risk of cancer: a meta-analysis

Study protocol

Study design and methods for the Breast Cancer and Exercise Trial in Alberta (BETA)

Research article

Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma

Research article

SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

Research article

microRNA alterations in ALDH positive mammary epithelial cells: a crucial contributing factor towards breast cancer risk reduction in case of early pregnancy

Research article

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits